Welcome to WestVirginiaLifeScience.com

Our network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About West Virginia's BioHistory

Through West Virginia BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of West Virginia.

Local News...

Free News Release Posting & Archiving Service


• Osiris Therapeutics reports first quarter 2008 financial results  Osiris Therapeutics announced its results for the first quarter of 2008. For the first quarter of 2008, Osteocel sales were $7.5 million, compared to $2.0 million for the same period of the prior year.
  Osiris Therapeutics, Inc.  May 09, 2008  
  
  
• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• Osiris receives approval for use of Prochymal under FDA expanded access treatment program  Osiris Therapeutics announced it has been given clearance by the U.S. Food and Drug Administration to initiate an expanded access treatment program for Prochymal, making the investigational stem cell product available to children with life-threatening Graft vs. Host Disease.
  Osiris Therapeutics, Inc.  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• POZEN reports first quarter 2008 results  POZEN announced results for the first quarter ended March 31, 2008. POZEN reported a net loss of ($7.4) million, or ($0.25) per share on a diluted basis, for the first quarter of 2008, compared to a net loss of ($2.1) million, or ($0.07) per share on a diluted basis, for the first quarter of 2007.
  POZEN Inc.  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/12/2008: AIBS Annual Meeting: Climate, Environment, and Infectious Diseases
• 05/13/2008: 2008 Healthcare Investor & Corporate Development Conference

More... | Submit Event | Event Advertising...